Abstract | INTRODUCTION: Second generation antipsychotic (AP)s remain the gold-standard treatment for schizophrenia and are widely used on- and off-label for other psychiatric illnesses. However, these agents cause serious metabolic side-effects. The hypothalamus is the primary brain region responsible for whole body energy regulation, and disruptions in energy sensing (e.g. insulin signaling) and inflammation in this brain region have been implicated in the development of insulin resistance and obesity. To elucidate mechanisms by which APs may be causing metabolic dysregulation, we explored whether these agents can directly impact energy sensing and inflammation in hypothalamic neurons. METHODS: RESULTS: CONCLUSIONS:
|
Authors | Chantel Kowalchuk, Pruntha Kanagasundaram, Denise D Belsham, Margaret K Hahn |
Journal | Psychoneuroendocrinology
(Psychoneuroendocrinology)
Vol. 104
Pg. 42-48
(06 2019)
ISSN: 1873-3360 [Electronic] England |
PMID | 30802709
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2019. Published by Elsevier Ltd. |
Chemical References |
- Antipsychotic Agents
- Insulin
- Aripiprazole
- Clozapine
- Olanzapine
|
Topics |
- Animals
- Antipsychotic Agents
(metabolism, pharmacology)
- Aripiprazole
(metabolism, pharmacology)
- Cell Line
- Clozapine
(metabolism, pharmacology)
- Energy Metabolism
(drug effects)
- Hypothalamus
(drug effects, metabolism)
- Inflammation
(metabolism)
- Insulin
(metabolism)
- Insulin Resistance
(physiology)
- MAP Kinase Signaling System
(drug effects, physiology)
- Neurons
(drug effects)
- Olanzapine
(metabolism, pharmacology)
- Phosphorylation
(drug effects)
- Rats
- Schizophrenia
(drug therapy, metabolism)
- Signal Transduction
(drug effects)
|